Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H23N7O7 |
Molecular Weight | 473.4393 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1
InChI
InChIKey=VVIAGPKUTFNRDU-STQMWFEESA-N
InChI=1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)/t12-,13-/m0/s1
Levoleucovorin is the pharmacologically active isomer of leucovorin or 5-formyl tetrahydrofolic acid, a folate analog . Levoleucovorin does not require reduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of “onecarbon” moieties. Administration of levoleucovorin can counteract the therapeutic and toxic effects of folic acid antagonists such as methotrexate, which act by inhibiting dihydrofolate reductase. Levoleucovorin can enhance the therapeutic and toxic effects of fluoropyrimidines used in cancer therapy such as 5-fluorouracil. 5-fluorouracil is metabolized to 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), which binds to and inhibits thymidylate synthase (an enzyme important in DNA repair and replication). Levoleucovorin is readily converted to another reduced folate, 5,10-methylenetetrahydrofolate, which acts to stabilize the binding of FdUMP to thymidylate synthase and thereby enhances the inhibition of this enzyme. Fusilev® (levoleucovorin) is approved by FDA for i) rescue after high-dose methotrexate therapy in osteosarcoma, ii) diminishing the toxicity and counteracting the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists and iii) in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | FUSILEV Approved UseFusilev is a folate analog indicated for: Rescue after high-dose methotrexate therapy in osteosarcoma. Diminishing the toxicity and counteracting the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists. Use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer. Launch Date1.20484803E12 |
|||
Palliative | FUSILEV Approved UseFusilev is a folate analog indicated for: Rescue after high-dose methotrexate therapy in osteosarcoma. Diminishing the toxicity and counteracting the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists. Use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer. Launch Date1.20484803E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10895 ng/mL |
200 mg/m² single, intravenous dose: 200 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
LEVOLEUCOVORIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
340 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8405015/ |
12.5 mg single, oral dose: 12.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOMEFOLIC ACID serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
275 ng/mL |
15 mg single, intravenous dose: 15 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
LEVOMEFOLIC ACID serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4930 ng/mL |
200 mg/m² single, intravenous dose: 200 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
LEVOMEFOLIC ACID unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
30719 ng × h/mL |
200 mg/m² single, intravenous dose: 200 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
LEVOLEUCOVORIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1563 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8405015/ |
12.5 mg single, oral dose: 12.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOMEFOLIC ACID serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
52105 ng × h/mL |
200 mg/m² single, intravenous dose: 200 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
LEVOMEFOLIC ACID unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.8 h |
15 mg single, intravenous dose: 15 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
LEVOMEFOLIC ACID serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
250 mg/m2 1 times / 2 weeks multiple, intravenous Higher than recommended Dose: 250 mg/m2, 1 times / 2 weeks Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / 2 weeks Co-administed with:: irinotecan, i.v(200 mg/m2) Sources: Page: p.2075-fluorouracil, i.v(850 mg/m2) |
unhealthy, 39 n = 254 Health Status: unhealthy Condition: Colorectal cancer Age Group: 39 Sex: M+F Population Size: 254 Sources: Page: p.207 |
Other AEs: Neutropenia... |
300 mg/m2 1 times / day multiple, intravenous Highest studied dose Dose: 300 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 300 mg/m2, 1 times / day Co-administed with:: etoposide, i.v(100 mg/m2/day; days 2-4) Sources: Page: p.3205-fluorouracil, i.v(500 mg/m2/day; days 1-5) |
unhealthy, 66 n = 36 Health Status: unhealthy Condition: Gastric cancer Age Group: 66 Sex: M+F Population Size: 36 Sources: Page: p.320 |
Other AEs: Leucopenia... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Neutropenia | grade 4, 15% | 250 mg/m2 1 times / 2 weeks multiple, intravenous Higher than recommended Dose: 250 mg/m2, 1 times / 2 weeks Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / 2 weeks Co-administed with:: irinotecan, i.v(200 mg/m2) Sources: Page: p.2075-fluorouracil, i.v(850 mg/m2) |
unhealthy, 39 n = 254 Health Status: unhealthy Condition: Colorectal cancer Age Group: 39 Sex: M+F Population Size: 254 Sources: Page: p.207 |
Leucopenia | grade 4 | 300 mg/m2 1 times / day multiple, intravenous Highest studied dose Dose: 300 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 300 mg/m2, 1 times / day Co-administed with:: etoposide, i.v(100 mg/m2/day; days 2-4) Sources: Page: p.3205-fluorouracil, i.v(500 mg/m2/day; days 1-5) |
unhealthy, 66 n = 36 Health Status: unhealthy Condition: Gastric cancer Age Group: 66 Sex: M+F Population Size: 36 Sources: Page: p.320 |
PubMed
Title | Date | PubMed |
---|---|---|
Lack of catalytic activity of a murine mRNA cytoplasmic serine hydroxymethyltransferase splice variant: evidence against alternative splicing as a regulatory mechanism. | 2001 Apr 24 |
|
Re-evaluation of the metabolism of oral doses of racemic carbon-6 isomers of formyltetrahydrofolate in human subjects. | 2001 Jun |
|
Ontogeny of hepatic enzymes involved in serine- and folate-dependent one-carbon metabolism in rabbits. | 2001 May |
|
Mitochondria from cultured cells derived from normal and thiamine-responsive megaloblastic anemia individuals efficiently import thiamine diphosphate. | 2002 Apr 25 |
|
Cloning and characterization of methenyltetrahydrofolate synthetase from Saccharomyces cerevisiae. | 2002 Jun 7 |
|
Transport of 5-formyltetrahydrofolate into primary cultured cerebellar granule cells. | 2003 Feb 7 |
|
Specific and sensitive quantification of folate vitamers in foods by stable isotope dilution assays using high-performance liquid chromatography-tandem mass spectrometry. | 2003 May |
|
Cerebral folate deficiency. | 2004 Dec |
|
Lack of impact of the loss of constitutive folate receptor alpha expression, achieved by RNA Interference, on the activity of the new generation antifolate pemetrexed in HeLa cells. | 2004 Dec 1 |
|
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity. | 2004 Jan 26 |
|
Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier. | 2004 Sep 15 |
|
5-Formyltetrahydrofolate is an inhibitory but well tolerated metabolite in Arabidopsis leaves. | 2005 Jul 15 |
|
Inhibition of 5,10-methenyltetrahydrofolate synthetase. | 2007 Feb 15 |
|
pH stability of individual folates during critical sample preparation steps in prevision of the analysis of plant folates. | 2007 Nov-Dec |
|
Folate content in sea buckthorn berries and related products (Hippophaë rhamnoides L. ssp. rhamnoides): LC-MS/MS determination of folate vitamer stability influenced by processing and storage assessed by stable isotope dilution assay. | 2008 May |
|
High-dose folate and dietary purines promote scavenging of peroxynitrite-derived radicals--clinical potential in inflammatory disorders. | 2009 Nov |
|
One-carbon metabolism in plants: characterization of a plastid serine hydroxymethyltransferase. | 2010 Aug 15 |
|
Cerebral folate deficiency presenting as adolescent catatonic schizophrenia: a case report. | 2010 Jul |
|
The effect of folinic acid supplementation on homocysteine concentrations in newborns. | 2010 Nov |
|
Mutation of the proton-coupled folate transporter gene (PCFT-SLC46A1) in Turkish siblings with hereditary folate malabsorption. | 2010 Nov |
|
Properties of the Arg376 residue of the proton-coupled folate transporter (PCFT-SLC46A1) and a glutamine mutant causing hereditary folate malabsorption. | 2010 Nov |
Sample Use Guides
Fusilev Rescue After High-Dose Methotrexate Therapy:
Fusilev rescue recommendations are based on a methotrexate dose of 12 grams/m2 administered by intravenous infusion over 4 hours. Fusilev rescue at a dose of 7.5 mg (approximately 5 mg/m2) every 6 hours for 10 doses starts 24 hours after the beginning of the methotrexate infusion.
Fusilev Administration in Combination with 5-Fluorouracil (5-FU):
The following regimens have been used historically for the treatment of colorectal cancer:
1. Fusilev is administered at 100 mg/m2 by slow intravenous injection over a minimum of 3 minutes, followed by 5-FU at 370 mg/m2 by intravenous
injection.
2. Fusilev is administered at 10 mg/m by 2 intravenous injection followed by 5-FU at 425 mg/m2 by intravenous injection.
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
554
Created by
admin on Fri Dec 15 16:15:47 UTC 2023 , Edited by admin on Fri Dec 15 16:15:47 UTC 2023
|
||
|
WHO-ATC |
V03AF10
Created by
admin on Fri Dec 15 16:15:47 UTC 2023 , Edited by admin on Fri Dec 15 16:15:47 UTC 2023
|
||
|
WHO-ATC |
V03AF04
Created by
admin on Fri Dec 15 16:15:47 UTC 2023 , Edited by admin on Fri Dec 15 16:15:47 UTC 2023
|
||
|
NCI_THESAURUS |
C2078
Created by
admin on Fri Dec 15 16:15:47 UTC 2023 , Edited by admin on Fri Dec 15 16:15:47 UTC 2023
|
||
|
FDA ORPHAN DRUG |
48590
Created by
admin on Fri Dec 15 16:15:47 UTC 2023 , Edited by admin on Fri Dec 15 16:15:47 UTC 2023
|
||
|
FDA ORPHAN DRUG |
48490
Created by
admin on Fri Dec 15 16:15:47 UTC 2023 , Edited by admin on Fri Dec 15 16:15:47 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID4023204
Created by
admin on Fri Dec 15 16:15:47 UTC 2023 , Edited by admin on Fri Dec 15 16:15:47 UTC 2023
|
PRIMARY | |||
|
SUB34736
Created by
admin on Fri Dec 15 16:15:47 UTC 2023 , Edited by admin on Fri Dec 15 16:15:47 UTC 2023
|
PRIMARY | |||
|
C1559
Created by
admin on Fri Dec 15 16:15:47 UTC 2023 , Edited by admin on Fri Dec 15 16:15:47 UTC 2023
|
PRIMARY | |||
|
68538-85-2
Created by
admin on Fri Dec 15 16:15:47 UTC 2023 , Edited by admin on Fri Dec 15 16:15:47 UTC 2023
|
PRIMARY | |||
|
877015
Created by
admin on Fri Dec 15 16:15:47 UTC 2023 , Edited by admin on Fri Dec 15 16:15:47 UTC 2023
|
PRIMARY | RxNorm | ||
|
DB11596
Created by
admin on Fri Dec 15 16:15:47 UTC 2023 , Edited by admin on Fri Dec 15 16:15:47 UTC 2023
|
PRIMARY | |||
|
4384
Created by
admin on Fri Dec 15 16:15:47 UTC 2023 , Edited by admin on Fri Dec 15 16:15:47 UTC 2023
|
PRIMARY | |||
|
63606
Created by
admin on Fri Dec 15 16:15:47 UTC 2023 , Edited by admin on Fri Dec 15 16:15:47 UTC 2023
|
PRIMARY | |||
|
990S25980Y
Created by
admin on Fri Dec 15 16:15:47 UTC 2023 , Edited by admin on Fri Dec 15 16:15:47 UTC 2023
|
PRIMARY | |||
|
990S25980Y
Created by
admin on Fri Dec 15 16:15:47 UTC 2023 , Edited by admin on Fri Dec 15 16:15:47 UTC 2023
|
PRIMARY | |||
|
100000128077
Created by
admin on Fri Dec 15 16:15:47 UTC 2023 , Edited by admin on Fri Dec 15 16:15:47 UTC 2023
|
PRIMARY | |||
|
135398559
Created by
admin on Fri Dec 15 16:15:47 UTC 2023 , Edited by admin on Fri Dec 15 16:15:47 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)